Philanthropic trust awards $2m biomedical research grantsBY JAMES FERNYHOUGH | WEDNESDAY, 16 OCT 2013 12:35PMThe Ramaciotti Foundations, a philanthropic trust managed by Perpetual, last night announced the recipients of the annual Ramaciotti Awards for biomedical research. Related News |
Editor's Choice
Mercer rolls out new corporate super plan
Mercer Super has launched a new corporate superannuation plan for employers of all sizes called Mercer Business Super.
Australian Retirement Trust applies new investment exclusion
The mega super fund has added to its list of exclusions, to come into effect from July 1.
Insignia FUM grows by $11bn, completes platform migration
Insignia Financial has given a quarterly business update, seeing funds under management grow 3.9% to $312.3 billion.
Former Diverger managing director joins VBP
David Carney is stepping back from managing Vital Business Partners (VBP), appointing Nathan Jacobsen to take over as chief executive.
Products
Expert Feed
Why advisers should consider offering general insurance to HNW clients
I have read many articles over the years about servicing high-net-worth (HNW) clients in the financial services industry.
The role of AI in financial planning: Insights from the US
Ever since ChatGPT burst onto the scene late last year, generative AI has been front and centre of business discussions and financial planning, just like ...
Considerations when nominating a charity for your super upon death
There has been a lot of talk lately about the upcoming great wealth transfer, and you might be wondering where charities fit into all this.
The end of free money
With institutional investors prudently reassessing their risks in current market conditions and seeking safe havens in alternatives such as secured private ...
Featured Profile
Robert De Dominicis
CHIEF EXECUTIVE OFFICER
GBST HOLDINGS LIMITED
GBST HOLDINGS LIMITED
It was during a family sojourn to the seaside town of Pescara, Italy, Rob DeDominicis first laid eyes on what would become the harbinger of his future. Andrew McKean writes.
